Ann: CELLMID QUARTERLY OPERATIONAL UPDATE, page-15

Well everyone must be on holidays or something as you aren't getting very many replies as yet.

Some unknowns there, mate or matess, but a quarterly announcement is due late January that may indicate a positive cash flow position from 2.0 million in sales, 1.3 million in a share placement and 900,000 in a R&D grant, There may be some royalties from Pacific Edge as well.

Repeat sales from the last quarter wont show up until a quarter later due to the nature of the product which requires 3 months application to take effect.

So if we had say .5 million spent on the 27 th DEC million dollar day by buyers we wouldnt expect them to be returning until late March, to be confirmed as a returning customer.

This is where the YPB setup will be able to give customers a prod if they are getting close to running out through the New Website,( under development).

There is always this lag, but once they are into the benefits and can see the results the customers may be receptive to ongoing application of Evolis or Lexilis. The thing to remember is that the supply of FGF5 inhibitors has to be maintained for results.

Cheers and good luck in your research and DD. Very sensible and welcome aboard if you climb into it.